A phase I trial to investigate the efficacy of adoptive T cell therapy (TT 12) in oropharyngeal cancer (OPC) and cervical cancer
Latest Information Update: 16 Jan 2016
Price :
$35 *
At a glance
- Drugs TT 12 (Primary)
- Indications Cervical cancer; Oropharyngeal cancer
- Focus Adverse reactions
- Sponsors Tessa Therapeutics
- 13 Jan 2016 New trial record